

in one of the sales of that drug failed to bear the name, and quantity or proportion of each such derivative and in juxtaposition therewith the statement, "Warning—May be habit forming."

Further misbranding, Section 502 (f) (1), none of the repackaged drugs bore labeling containing directions for use.

DISPOSITION: March 24, 1950. Pleas of guilty having been entered, the court fined the company \$300, defendant Portman \$100, and defendant Rundt \$200, plus costs.

3083. Misbranding of seconal sodium capsules and sodium amytal capsules. U. S. v. Ontario Pharmacy, Inc., and Joseph V. Gadzinski. Pleas of guilty. Fines of \$300 against corporation and \$900 against individual, plus costs. (F. D. C. No. 28118. Sample Nos. 15866-K to 15868-K, incl.)

INFORMATION FILED: January 17, 1950, Northern District of Illinois, against Ontario Pharmacy, Inc., Chicago, Ill., and Joseph V. Gadzinski, secretary-treasurer of the corporation.

INTERSTATE SHIPMENT: Prior to the date of the sales of the drugs by the defendant as hereinafter described, the drugs were manufactured in the State of Indiana and shipped in interstate commerce into the State of Illinois.

ALLEGED VIOLATION: On or about February 20, 22, and 23, 1949, while the drugs were being held for sale after shipment in interstate commerce, the defendant caused various quantities of the drugs to be repackaged and sold to various persons without a prescription, which acts of the defendant resulted in the repackaged drugs being misbranded.

NATURE OF CHARGE: Misbranding, Sections 502 (b) (1) and (b) (2), the repackaged drugs failed to bear labels containing the name and place of business of the manufacturer, packer, or distributor, and a statement of the quantity of the contents.

Further misbranding, Section 502 (d), the drugs contained chemical derivatives of barbituric acid, which derivatives had been by the Administrator of the Federal Security Agency, found to be, and by regulations designated as, habit forming; and the labels of the repackaged drugs failed to bear the name, and quantity or proportion of each such derivative and in juxtaposition therewith the statement "Warning—May be habit forming."

Further misbranding, Section 502 (f) (1), the repackaged *seconal sodium capsules* bore no labeling containing directions for use.

DISPOSITION: April 10, 1950. A plea of guilty having been entered, the court fined the corporation \$300 and the individual \$900, plus costs.

3084. Misbranding of seconal sodium capsules, thyroid tablets, pentobarbital sodium capsules, and Metandren Linguets. U. S. v. Jack Golder (Pine Lawn Cut Rate Drugs). Plea of guilty. Fine, \$500. (F. D. C. No. 26738. Sample Nos. 45743-K, 45950-K, 45953-K to 45955-K, incl.)

INFORMATION FILED: October 12, 1949, Eastern District of Missouri, against Jack Golder, trading as Pine Lawn Cut Rate Drugs, at Pine Lawn, Mo.

INTERSTATE SHIPMENT: Between the approximate dates of October 2, 1947, and November 13, 1948, from Indianapolis, Ind., Chicago, Ill., and Summit, N. J., into the State of Missouri, of quantities of *seconal sodium capsules, thyroid tablets, pentobarbital sodium capsules, and Metandren Linguets.*

LABEL, WHEN SHIPPED: "Seconal Sodium 1½ grs.," "1 Grain Thyroid Tablets U. S. P.," "Pentobarbital Sodium Capsules Yellow 1½ grain U. S. P.," and